GARS1

Glycine--tRNA ligase · P41250 · GARS1 on Sugi Atlas →

453 patent compounds predicted against GARS1, 312 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Crenolanib (SCHEMBL2730601)	1.00	1/20
Crenolanib (SCHEMBL29350134)	1.00	1/20
Crenolanib (SCHEMBL29352568)	1.00	1/20
Crenolanib (SCHEMBL30002138)	1.00	1/20
SCHEMBL22567082	0.86	1/20
SCHEMBL5662568	0.85	1/20
Crenolanib (SCHEMBL4681285)	0.85	1/20
Crenolanib (SCHEMBL29352554)	0.85	1/20
Crenolanib (SCHEMBL29361948)	0.85	1/20
SCHEMBL27030604	0.85	1/20
SCHEMBL30775111	0.85	1/20
SCHEMBL23026363	0.82	1/20
SCHEMBL3191766	0.80	1/20
SCHEMBL27030775	0.80	1/20
SCHEMBL30441378	0.80	1/20
SCHEMBL3180117	0.79	1/20
SCHEMBL3189249	0.78	1/20
SCHEMBL3190082	0.78	1/20
SCHEMBL3190135	0.78	1/20
SCHEMBL3182258	0.76	1/20

Clinical trials — most relevant to GARS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)	PHASE1/PHASE2	ENROLLING_BY_INVITATION
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Homocystinuria: Treatment With N-Acetylcysteine	PHASE2	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
Quantifying Disease Progression in LBSL	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Genomic of CONgenital Sideroblastic Anemias	nan	RECRUITING
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome	nan	COMPLETED
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions	nan	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Genetic Analysis of Fraser Syndrome and Fryns Syndrome	nan	COMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Genetic Analysis of Parkinson's Disease	nan	COMPLETED
Natural History of the Leukodystrophies	nan	COMPLETED
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions	nan	WITHDRAWN
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
Microarray Analysis in Syndromic Obesity	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GARS1 binder may also engage these)

Protein	Name	Similarity
Q5RBL1	—	1.000	Q5RBL1 →
Q9CZD3	—	1.000	Q9CZD3 →
Q5I0G4	—	0.999	Q5I0G4 →
Q04451	—	0.998	Q04451 →
Q10039	—	0.998	Q10039 →
P38088	—	0.995	P38088 →
O23627	—	0.994	O23627 →
Q10179	—	0.993	Q10179 →
Q0V9S0	—	0.991	Q0V9S0 →
Q9VUK8	—	0.991	Q9VUK8 →
Q6DRC0	—	0.991	Q6DRC0 →
Q8RWT8	—	0.991	Q8RWT8 →
Q9SSK1	—	0.990	Q9SSK1 →
SARS1	Serine--tRNA ligase, cytoplasmic	0.988	landscape →
Q6P799	—	0.988	Q6P799 →
Q06817	—	0.987	Q06817 →
Q4R4U9	—	0.987	Q4R4U9 →
Q9M084	—	0.986	Q9M084 →
Q9ZPI1	—	0.986	Q9ZPI1 →
Q9FYR6	—	0.986	Q9FYR6 →
P49696	—	0.986	P49696 →
P04801	—	0.986	P04801 →
Q8CFX8	—	0.985	Q8CFX8 →
P50475	—	0.985	P50475 →
Q6F2U9	—	0.985	Q6F2U9 →
P21894	—	0.985	P21894 →
Q8BLY2	—	0.985	Q8BLY2 →
KARS1	Lysine--tRNA ligase	0.984	landscape →
Q5RC02	—	0.984	Q5RC02 →
Q9LJE2	—	0.984	Q9LJE2 →